CL2009001081A1 - Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo. - Google Patents

Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo.

Info

Publication number
CL2009001081A1
CL2009001081A1 CL2009001081A CL2009001081A CL2009001081A1 CL 2009001081 A1 CL2009001081 A1 CL 2009001081A1 CL 2009001081 A CL2009001081 A CL 2009001081A CL 2009001081 A CL2009001081 A CL 2009001081A CL 2009001081 A1 CL2009001081 A1 CL 2009001081A1
Authority
CL
Chile
Prior art keywords
vehicle
particulate
polybutylcyan
acrylated
mixing
Prior art date
Application number
CL2009001081A
Other languages
English (en)
Inventor
Mehmet Fidanboylu
Irene Papanicolaou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001081(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2009001081A1 publication Critical patent/CL2009001081A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento para producir un vehículo en forma de partículas que comprende disolver polibutilcianoacrilado en un disolvente orgánico para formar una solución polimérica, añadir una solución acuosa, mezclar y obtener el vehículo en forma de partículas; composición farmacéutica que comprende dicho vehículo.
CL2009001081A 2008-05-06 2009-05-05 Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo. CL2009001081A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
CL2009001081A1 true CL2009001081A1 (es) 2010-09-24

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2009001076A CL2009001076A1 (es) 2008-05-06 2009-05-05 Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
CL2009001077A CL2009001077A1 (es) 2008-05-06 2009-05-05 Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
CL2009001081A CL2009001081A1 (es) 2008-05-06 2009-05-05 Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo.
CL2009001080A CL2009001080A1 (es) 2008-05-06 2009-05-05 Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2009001076A CL2009001076A1 (es) 2008-05-06 2009-05-05 Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
CL2009001077A CL2009001077A1 (es) 2008-05-06 2009-05-05 Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2009001080A CL2009001080A1 (es) 2008-05-06 2009-05-05 Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.

Country Status (11)

Country Link
US (1) US20110064821A1 (es)
EP (2) EP2271323A2 (es)
JP (1) JP2011522792A (es)
KR (3) KR20110010760A (es)
AR (4) AR071633A1 (es)
CA (1) CA2721241A1 (es)
CL (4) CL2009001076A1 (es)
PE (4) PE20091829A1 (es)
TW (4) TW201012490A (es)
UY (4) UY31807A (es)
WO (1) WO2009135853A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064819A1 (en) * 2008-05-06 2011-03-17 Andrew Beaton Encapsulation of biologically active agents
US9504759B2 (en) 2011-08-11 2016-11-29 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
US20170189344A1 (en) * 2014-05-30 2017-07-06 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
EP3154524B1 (en) * 2014-06-12 2021-12-15 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
EP4299058A3 (en) 2014-06-24 2024-03-27 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US12357582B2 (en) * 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220031630A1 (en) * 2018-09-13 2022-02-03 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
AU3462193A (en) * 1993-02-15 1994-08-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
ATE197124T1 (de) * 1993-09-09 2000-11-15 Schering Ag Wirkstoffe und gas enthaltende mikropartikel
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
CA2452382A1 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
ES2318531T3 (es) 2004-09-14 2009-05-01 Nanodel Technologies Gmbh Vehiculo de administracion que contiene nanoparticulas.
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
DK2177536T3 (da) 2006-03-30 2014-07-14 Glaxo Group Ltd Antistoffer mod amyloid-beta-peptid
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
EP2271323A2 (en) 2011-01-12
JP2011522792A (ja) 2011-08-04
UY31809A (es) 2009-12-14
TW201012489A (en) 2010-04-01
UY31808A (es) 2009-12-14
CL2009001077A1 (es) 2010-09-24
PE20091965A1 (es) 2010-01-09
AR071634A1 (es) 2010-06-30
KR20110015604A (ko) 2011-02-16
PE20091829A1 (es) 2009-12-12
TW201012488A (en) 2010-04-01
PE20091882A1 (es) 2009-12-24
CL2009001080A1 (es) 2010-09-24
EP2441447A1 (en) 2012-04-18
AR072668A1 (es) 2010-09-15
UY31810A (es) 2009-12-14
AR072359A1 (es) 2010-08-25
UY31807A (es) 2009-12-14
WO2009135853A2 (en) 2009-11-12
AR071633A1 (es) 2010-06-30
TW201012490A (en) 2010-04-01
KR20110010758A (ko) 2011-02-07
WO2009135853A3 (en) 2011-05-12
KR20110010760A (ko) 2011-02-07
US20110064821A1 (en) 2011-03-17
CA2721241A1 (en) 2009-11-12
CL2009001076A1 (es) 2010-09-24

Similar Documents

Publication Publication Date Title
AR091212A1 (es) Cilindros de conduccion termal para el uso en articulos generadores de aerosol
CR8412S (es) Vehiculo de cuatro ruedas
CR10633S (es) Botella
BRPI0806957A2 (pt) Processo para produzir um ácido polilático, ácido polilático, e, artigo moldado.
ECSP11011078A (es) Agente de sostén
AR077237A1 (es) Polimeros colorantes
BRPI0917107A2 (pt) tanque de combustível de plástico, e, processo para produzir um tanque de combustível de plástico.
BRPI0911045A2 (pt) processo para a produção contínua de um poliéster biodegradável, poliéster biodragradável, mistura de poliéster biodegradável, e, uso de poliésteres.
BRPI0912921A2 (pt) complexo metal-ligante, catalisador e processo para preparo de uma poliolefina
BRPI0907909A2 (pt) Sistema, e, processo para a produção e uso do mesmo
BRPI0812054A2 (pt) Processo para preparar compostos, e, compostos.
BRPI0920098A2 (pt) módulo com diodos eletroluminescentes para veículo, utilização do módulo, veículo e processo de fabricação de módulo com diodos eletroluminescentes para veículo
BRPI0911767A2 (pt) Processo, e, composto.
BRPI0916986A2 (pt) dispositivo do mancal de desengate de embreagem, bem como, processo para a fabricação do mesmo
BRPI0906091A2 (pt) Polímetro etilênico e processo para preparar polímetros etilênicos.
CL2011000393A1 (es) Metodo para preparar una microesfera de liberacion sostenidaque comprende disolver la sustancia activa y un polimero biodegradable en solvente acuoso y no acuoso respectivamente, formar una emulsion entre ambas soluciones, adicionarle un cosolvente y agregarla a un solvente acuoso para formar la microesfera y remover el solvente organico.
BRPI0814980A2 (pt) Processo para produzir um composto, e, composto.
CL2008000156A1 (es) Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
BRPI0816429A2 (pt) microorganismo, e, método para a produção de um l-aminoácido.
CL2011002974A1 (es) Metodo de preparacion de hidrocloruro de nalmefeno utilizando 2-metil-tetrahidrofurano como solvente en una reaccion de witting.
BRPI0923911A2 (pt) partícula de polímero termoplástico, expansível, e, processo para a produção de partículas de polímero termoplástico, expansível.
BRPI0908833A2 (pt) Composição polimérica elastomérica biodegradável, processo para preparar uma composição polimérica, e, uso da composição polimérica.
AP2011005545A0 (en) Methods and processes for producing organic acids.
CL2009001080A1 (es) Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
BRPI0910037A2 (pt) método para fabricar polilactídeo estável